

SCIENCEDOMAIN international

www.sciencedomain.org

SDI Review Form 1.6

Journal Name:	British Journal of Medicine and Medical Research
Manuscript Number:	Ms_BJMMR_25855
Title of the Manuscript:	Analyze of risk factors affecting the outcomes of docetaxel – prednisolone combination in the treatment of metastatic castration-resistant prostate cancer
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of 'lack of Novelty', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

SCIENCEDOMAIN international



SDI Review Form 1.6

PART 1: Review Comments

		the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	The paper shows that a DP combination therapy is a suitable and effective regimen with acceptable tolerance in the treatment of men with CRPC. It adds to the knowledge of risk factors in the use of taxanes as chemotherapeutics and shows that chemotherapy outcomes following DP chemotherapy in patients with CRPC can be followed by monitoring serum levels of ALP, total proteins and albumin. Title: was the use of prednisolone instead of prednisone, as reported throughout the manuscript, intentional by the authors?	
Minor REVISION comments Optional/General comments	A few typos throughout the text need to be corrected (general editing spacing rules regarding punctuation are often neglected; line 81: criteria is the correct plural for criterion; line 37: hormonotheapy; line 155: doxetaxel; line 166: comma must be removed).	

Reviewer Details:

Name:	Marina Quartu
Department, University & Country	Dept Biomedical Sciences, University of Cagliari, Italy